As of November 6, 2026, one holder's latest Schedule 13D or 13G filing report owning 5% or more of Cidara Therapeutics, Inc. The largest reported stake is The Vanguard Group's, at 6.38%. 25 filings are on record since July 2, 2025 (Schedule 13G, January 30, 2026).
Sell to companies like Cidara Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Holder: Point72 Asset Management, L.P. · Percent: 1.4% · SCHEDULE 13G/A
- · Holder: BCLS Fund III Investments, LP · Percent: 0% · SCHEDULE 13G/A
- · Holder: Vivo Opportunity Fund Holdings, L.P. · Percent: 0% · SCHEDULE 13G/A
- · Holder: The Vanguard Group · Percent: 6.38% · SCHEDULE 13G
- · Holder: RA Capital Management, L.P. · Percent: 0% · SCHEDULE 13D/A
Cidara Therapeutics, Inc. has 25 Schedule 13D or 13G filings on record since 2025-07-02. 1 holder's latest filing reports 5% or more of common stock, $0.0001 par value per share. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| The Vanguard Group | 6.38% | 2,007,193 | SCHEDULE 13G, 2026-01-30 | 2025-12-31 |
| Adage Capital Management, L.P. | 4.97% | 1,100,000 | SCHEDULE 13G/A, 2025-08-12 | 2025-06-30 |
| BlackRock, Inc. | 4.6% | 1,163,607 | SCHEDULE 13G/A, 2025-10-17 | 2025-09-30 |
| Bvf Partners L P | 4.4% | 1,189,165 | SCHEDULE 13G/A, 2025-10-17 | 2025-10-15 |
| Paradigm BioCapital Advisors LP | 3.3% | 961,164 | SCHEDULE 13G/A, 2025-11-14 | 2025-09-30 |
| Venrock Healthcare Capital Partners III, L.P. | 3.2% | 639,088 | SCHEDULE 13G/A, 2025-08-14 | 2025-06-30 |
| Commodore Capital LP | 2% | 585,000 | SCHEDULE 13G/A, 2025-11-14 | 2025-09-30 |
| Point72 Asset Management, L.P. | 1.4% | 450,000 | SCHEDULE 13G/A, 2026-02-17 | 2025-12-31 |
| RA Capital Management, L.P. | 0% | 0 | SCHEDULE 13D/A, 2026-01-09 | 2026-01-07 |
| Vivo Opportunity Fund Holdings, L.P. | 0% | 0 | SCHEDULE 13G/A, 2026-02-13 | 2026-01-07 |
| BCLS Fund III Investments, LP | 0% | 0 | SCHEDULE 13G/A, 2026-02-17 | 2025-12-31 |
| Canaan XII L.P. | 0% | 0 | SCHEDULE 13G/A, 2025-08-14 | 2025-06-30 |
| TCG Crossover GP II, LLC | 0% | 0 | SCHEDULE 13G/A, 2025-11-14 | 2025-09-30 |
Holding shares or following this stake? See who's behind Cidara Therapeutics, Inc. and the warning signs.
Free to see. No signup.
Keep reading
More on Cidara Therapeutics, Inc. and the records around it.
Cidara Therapeutics, Inc. elsewhere on the record
- Acquisition Jan 2026
- Who owns it
Companies that share a holder
- BCLS Fund III Investments, LP also filed stake reports on 3 other companies: ADARx Pharmaceuticals, Inc. (Oct 2026), Heartflow, Inc. (Aug 2026), DIANTHUS THERAPEUTICS, INC. (Nov 2025)
- Vivo Opportunity Fund Holdings, L.P. also filed stake reports on 20 other companies: ArriVent BioPharma, Inc. (Oct 2026), Clene Inc. (Aug 2026), Compass Therapeutics, Inc. (Aug 2026)
- TCG Crossover GP II, LLC also filed stake reports on 21 other companies: ALX Oncology Holdings Inc. (Aug 2026), First Tracks Biotherapeutics, Inc. (Aug 2026), Fulcrum Therapeutics, Inc. (Aug 2026)
Watch Cidara Therapeutics, Inc.
Get an email when Cidara Therapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Cidara Therapeutics, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Cidara Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Cidara Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
26 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Purpose of Transaction (Item 4)
RA Capital Management, L.P.
Item 4 of the Statement is hereby amended and supplemented as follows: The Offer and withdrawal rights expired as scheduled at one minute following 11:59 p.m., Eastern Time, on January 6, 2026 (such date and time, the "Expiration Time"). As of the Expiration Time, a sufficient number of shares were validly tendered and not validly withdrawn such that the minimum tender condition to the Offer was satisfied, and following the satisfaction of each other condition to the Offer, Parent and Purchaser irrevocably accepted for payment, on January 7, 2026, all shares that were validly tendered and not validly withdrawn pursuant to the Offer. Also on January 7, 2026, following consummation of the Offer, Purchaser merged with and into the Issuer, with the Issuer being the surviving corporation (the "Merger"). The Merger was governed by Section 251(h) of the Delaware General Corporation Law (the "DGCL"), with no vote of the stockholders of the Issuer required to consummate the Merger. Upon completion of the Merger, the Issuer became a wholly owned subsidiary of Parent, the Issuer's common stock was deregistered under the Securities and Exchange Act of 1934, as amended, and the Issuer's common stock ceased to be listed for trading on the Nasdaq Stock Market. At the Effective Time and pursuant to the terms and conditions of the Merger Agreement, each Common Share then outstanding (other than Common Shares (a) held by the Issuer (or in the Issuer's treasury), Parent, Purchaser, any …The first part of Item 4 of the SCHEDULE 13D/A filed 2026-01-09; the filing has the rest
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-07-02 | Commodore Capital LP | 5.5% | SCHEDULE 13G |
| 2025-07-17 | BlackRock, Inc. | 5.5% | SCHEDULE 13G |
| 2025-07-30 | Paradigm BioCapital Advisors LP | 5.6% | SCHEDULE 13G |
| 2025-08-11 | RA Capital Management, L.P. | 13.3% | SCHEDULE 13D/A |
| 2025-08-12 | Adage Capital Management, L.P. | 4.97% | SCHEDULE 13G/A |
| 2025-08-12 | Vivo Opportunity Fund Holdings, L.P. | 4.6% | SCHEDULE 13G/A |
| 2025-08-14 | Point72 Asset Management, L.P. | 7.6% | SCHEDULE 13G/A |
| 2025-08-14 | BCLS Fund III Investments, LP | 9.99% | SCHEDULE 13G/A |
| 2025-08-14 | Canaan XII L.P. | 0% | SCHEDULE 13G/A |
| 2025-08-14 | Venrock Healthcare Capital Partners III, L.P. | 3.2% | SCHEDULE 13G/A |
| 2025-10-17 | Bvf Partners L P | 5.2% | SCHEDULE 13G/A |
| 2025-10-17 | Bvf Partners L P | 4.4% | SCHEDULE 13G/A |
| 2025-10-17 | BlackRock, Inc. | 4.6% | SCHEDULE 13G/A |
| 2025-11-10 | RA Capital Management, L.P. | 10.7% | SCHEDULE 13D/A |
| 2025-11-14 | Point72 Asset Management, L.P. | 6.2% | SCHEDULE 13G/A |
| 2025-11-14 | Paradigm BioCapital Advisors LP | 3.3% | SCHEDULE 13G/A |
| 2025-11-14 | TCG Crossover GP II, LLC | 0% | SCHEDULE 13G/A |
| 2025-11-14 | BCLS Fund III Investments, LP | 9.99% | SCHEDULE 13G/A |
| 2025-11-14 | Commodore Capital LP | 2% | SCHEDULE 13G/A |
| 2025-11-17 | RA Capital Management, L.P. | 10.7% | SCHEDULE 13D/A |
| 2026-01-09 | RA Capital Management, L.P. | 0% | SCHEDULE 13D/A |
| 2026-01-30 | The Vanguard Group | 6.38% | SCHEDULE 13G |
| 2026-02-13 | Vivo Opportunity Fund Holdings, L.P. | 0% | SCHEDULE 13G/A |
| 2026-02-17 | Point72 Asset Management, L.P. | 1.4% | SCHEDULE 13G/A |
| 2026-02-17 | BCLS Fund III Investments, LP | 0% | SCHEDULE 13G/A |
Questions about who owns Cidara Therapeutics, Inc.
Who owns Cidara Therapeutics, Inc.?
On this page, one holder's latest ownership filing reports 5% or more of Cidara Therapeutics, Inc.: The Vanguard Group (6.38%, Schedule 13G, filed 2026-01-30).
When did The Vanguard Group buy into Cidara Therapeutics, Inc.?
The filings give report dates, not purchase dates. The earliest filing from The Vanguard Group on this page is the Schedule 13G, filed 2026-01-30, reporting 6.38%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 25 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Also on the record for Cidara Therapeutics, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| January 7, 2026 | Acquired by Merck Sharp & Dohme LLC | — | Acquisition | Source |
Tools for this story
Each opens in a new tab, filled in for Cidara Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.